Stockreport

AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA [Yahoo! Finance]

Biohaven Ltd. Common Shares  (BHVN) 
Last biohaven ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com
PDF Atogepant is a member of the gepant class of drug and is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRPs are potent vasodilators, particularly in th [Read more]